



## JAMES P. ALLISON INSTITUTE

### Signature Priority Committee fundraising guide

The [James P. Allison Institute™](#) at The University of Texas MD Anderson Cancer Center is where bold science meets urgent purpose. Established in 2022, the institute builds on the legacy of Nobel laureate James P. Allison, Ph.D., whose revolutionary discovery — that our immune systems can be unleashed to recognize, attack and remember cancer cells — launched the field of immunotherapy. Today, multiple immunotherapy drugs are standard treatment options, yielding remarkable results. Uniting the brightest minds in cancer research, clinical care and technology, the Allison Institute strives to rapidly advance breakthroughs to make immunotherapy more effective, more accessible and more personalized for all patients with any kind of cancer.

### A research and innovation powerhouse

As the world leader in saving lives through immunotherapy, the Allison Institute needs substantial funding to sustain its unique collaborations and interdisciplinary research model. Investments into the institute offer a powerful return — new cures for more patients than ever before. To reach our initial fundraising goal by August 2028, we will:

- **Recruit and retain the brightest talent (\$25 million):** As a research powerhouse, the Allison Institute needs world-class, pioneering talent — core, associate, assistant and adjunct members, along with postdoctoral fellows and graduate students — whose ideas and innovations will identify the next breakthroughs in immunotherapy.
- **Educate and expand outreach (\$550,000+):** Annual symposia, seminar series, next-generation colloquia, journal clubs and a clinical immunology working group will prepare the next generation of immunobiology physicians and scientists while enabling cross-pollination of ideas from the most brilliant minds.
- **Stay ahead of the curve: (\$4.5 million):** Specialized equipment and state-of-the-art technology are essential for Allison Institute researchers and clinicians to identify new immunotherapy targets and generate the next wave of cancer therapies. This technology will complement additional capital investments on MD Anderson’s South Campus, enabling the Institute to stay on the leading edge of immunotherapy research.
- **Offer access to hope (\$8 million):** MD Anderson is home to the world’s largest cancer clinical trials program, bringing cures from bench to bedside. Allison Institute researchers conduct trials that create novel treatments, expand therapeutic options for patients and redefine standards of care — but trials require tremendous investments for personnel salary, drug and patient care expenses, data management, and regulatory compliance.

After achieving these targets, we will pursue a second phase of fundraising, with the details and fundraising goal to be determined by the institute’s needs and opportunities at that time. As we push the next frontier in immunotherapy, the time is now — and the place is the Allison Institute.

#### As an essential member of the institute’s team, you have the passion, creativity and insight to:

**ACT** as an ambassador within your network and community, educating others about the Allison Institute.

**ADVISE** executive leadership, sharing your expertise and your insights about potential supporters or volunteers.

**INSPIRE** and **INFORM** others by hosting an event to introduce the Allison Institute, at which experts share the latest updates.

#### A new era for immunotherapy

Launched: [March 2022](#)

Led by:

[James P. Allison, Ph.D.](#)  
[Padmanee Sharma, M.D., Ph.D.](#)

Fundraising targets:

- \$100 million by Aug. 2028; \$8 million in matching funds available through Oct. 2025
- Second phase of fundraising TBD based on the institute’s developing needs and opportunities

Funds raised:

\$60 million+ committed as of July 2025

Watch: [A new era for immunotherapy with the James P. Allison Institute](#)